Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Grivas, Petros
Clinical Lecturer
Hematology/Oncology (Dept. of Internal Medicine)
University of Michigan
eRA COMMONS USER NAME (credential, e.g., agency login)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
-University of Patras School of Medicine, Greece
-University of Patras School of Medicine, Greece
M.D.
07/05
09/0506/06
-University of Patras School of Medicine, Greece
Ph.D.
05/09
-Drexel University College of
Hahnemann University Hospital
Medicine
/
06/0706/10
-University of Michigan
-University
of
Michigan
Administration Track Program)
07/1006/13
(Health
Care
09/12present
Medicine
Clinical/Laboratory Studies:
Molecular Biology
Biostatistics, Research
Methodology, Bioinformatics
Medical Oncology
Internal Medicine Residency
Hematology/Oncology
Fellowship
Health Care Administration,
Leadership (2-year program)
A. Personal Statement
I am a clinical and translational researcher with an interest in GU malignancies, particularly prostate and
urothelial cancers. My training in the Clinical/Laboratory Post-Graduate Studies and my lab experience from
my Ph.D. have nurtured my interest in translational research. My focus is on novel therapeutic interventions
via a molecular biology-based approach in the laboratory with the aim to translate results into clinical trials. I
participate in the multi-disciplinary research team at the University of Michigan interacting closely with
several scientists. My active involvement during my fellowship in several clinical trials under the mentorship
of Dr. Maha Hussain and Dr. David Smith has been a very useful experience. I have also worked at Dr.
Mark Day’s lab and generated preliminary data to support a clinical trial. I am aware of the importance of
frequent communication among project members and of constructing a realistic research plan, timeline, and
budget. The ultimate goal is to contribute to better patient care via discovery and innovative research.
B.
Positions and Honors
Positions and Employment
06/2007-06/2010 Resident, Dept. of Internal Medicine, Drexel University College of Medicine/Hahnemann
University Hospital
07/2010-06/2013 Fellow, Division of Hematology-Oncology, University of Michigan
07/2013-present
Clinical Lecturer, Division of Hematology/Oncology, University of Michigan
Other Experience and Professional Memberships
2005
Scientific Committee Member, Advances in Oncology Conference, Greece
2006
Faculty and Scientific Committee Member, Oncology Summer School for Medical
Students, Greece
2007
Scientific Committee Member, Advances in Oncology Conference, Greece
2007-Present
American College of Physicians (ACP)
2009
Editorial Board Member, Journal of Cancer Research and Experimental Oncology
2009
Editorial Board Member, Journal of Clinical Pathology and Forensic Medicine
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
2009
2009
2009-2011
2010
2010
2010
2011
2011
2011
2011
2011
2011
2011-present
2011-present
2011-present
2012
2012
2013
2011-2013
Honors
2000-2005
2001
2004
Editorial Board Member, Journal of Medical Genetics and Genomics
Peer-reviewer, European Journal of Gastroenterology & Hepatology
Peer-reviewer, Post-Graduate Medicine
Peer-reviewer, Transplant International
Editorial Board Member, Clinical Reviews and Opinions
Editorial Board Member, Global Journal of Surgery
Peer-reviewer, Journal of African Studies and Development
Peer-reviewer, Journal of Public Health and Epidemiology
Editorial Board Member, Recent patents on Biomarkers
Peer-reviewer, African Journal of Pharmacy and Pharmacology
Peer-reviewer, Universal Journal of Medicine & Dentistry
Peer-reviewer, Mini Reviews in Medicinal Chemistry
American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)
SWOG (also completed SWOG rotation during fellowship)
Peer-reviewer, Critical Reviews in Oncology/Hematology
Peer-reviewer, The International Journal of Biochemistry & Cell Biology
Peer-reviewer, The Pharmacogenomics Journal
Leader of Hematology/Oncology Fellowship QI Project
5 Academic Excellence Scholarships and Awards, Greek State Scholarship Foundation
Award/Honors of excellence in Biochemistry
1st award and highest grade in Oncology Exams: European School of Oncology (ΕSO)
“Oncology Course for Medical Students” (Cancer Treat Rev. 2007;33(5):419-26)
2004
European School of Oncology (ESO) Scholarship for training in Medical Oncology
2005
1st Award, Olympiad of Medical Knowledge, 11th Greek Medical Students Conference
2005
GlaxoSmithKline Scholarship for post-graduate studies in Medicine
2005
1st Award, Academic Excellence, Outstanding/Exceptional Graduate Medical Student /
highest academic rank, University of Patras, Greece
2007
Pennsylvania State Champion (1st place), “Medical Jeopardy” Competition, Hershey, PA
2008
Intern (PGY-1) of the academic year 2007-2008, Department of Internal Medicine,
Hahnemann University Hospital/ Drexel University College of Medicine
2008
3rd place, National US “Medical Jeopardy” Competition, Washington, DC
2009
Southeastern Pennsylvania Region Champion (1st place), “Medical Jeopardy”
2009
Pennsylvania State Champion (1st place), “Medical Jeopardy” Competition, Hershey, PA
2010
Resident of the month (January), Department of Internal Medicine, Hahnemann
University Hospital/Drexel University College of Medicine
2010
2nd Place, National US “Medical Jeopardy” Competition, Toronto, Canada
2011
AACR Workshop “Molecular Biology in Clinical Oncology” (Snowmass, CO)
2011
ASCO Conquer Foundation Merit Award (2012 GU ASCO Symposium)
2012
University of Michigan Hematology/Oncology Program “Shining Star Fellow” Award
2012
ASCO Conquer Foundation Merit Award (2012 Annual ASCO Meeting)
2012, 2013
NCCN Fellows Recognition Programs: “New Horizons in Quality Cancer Care”
2013
ASCO/AACR “Methods in Clinical Cancer Research” Workshop (Vail, CO)
2013
ASCO Conquer Foundation Merit Award (2013 Annual ASCO Meeting)
C. Selected Peer-reviewed Publications
1. Grivas PD, Hussain M, Hafez K, Daignault-Newton S, Wood D, Lee CT, Weizer A, Montie JE,
Hollenbeck B, Montgomery JS, Alva A, Smith DC. A Phase II Trial of Neoadjuvant nab-paclitaxel,
Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder.
Urology. 2013;82(1):111-7. PMID: 23706253
2. Grivas PD, Day M, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors
signaling. Am J Transl Res. 2011;3(4):362-373. PMID: 21904656
3. Grivas P, Liebert M, Kunju P, Day K, Day M, Hussain M. Targeting cancer stem cell-like phenotype
in bladder cancer (BC) cell lines. J Clin Oncol 29: 2011 (suppl; abstr e15102)
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
4. Grivas PD, Robins DM, Hussain M. Predicting response to hormonal therapy and survival in men
with hormone sensitive metastatic prostate cancer. CROH. 2012 Jun 15. PMID: 22705096
5. Grivas PD, Papavassiliou AG. Transcriptional corepressors in cancer: Emerging targets for
therapeutic intervention. Cancer. 2012 Dec 7. doi: 10.1002/cncr.27908. PMID: 23224952
6. Grivas PD, Kiaris H, Papavassiliou AG. Tackling transcription factors: challenges in antitumor
therapy. Trends Mol Med. 2011;17(10):537-8. PMID: 21775208
7. Grivas PD, Redman BG. Immunotherapy of kidney cancer. Curr Clinical Pharmacology;
2011;6(3):151-63. PMID: 21827390
8. Kefalopoulou Z, Tzelepi V, Zolota V, Grivas PD, Christopoulos C, Kalofonos H, Maraziotis T,
Sotiropoulou-Bonikou G. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear
receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse
patient prognosis. J Neurooncol. 2012;106(1):23-31. PMID: 21735116
9. Papachristou DJ, Korpetinou A, Giannopoulou E, Antonacopoulou AG, Papadaki H, Grivas P,
Scopa CD, Kalofonos HP. Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal
carcinomas. Virchows Arch. 2011;459(4):431-40. PMID: 21769619
10. V Saloura, PD Grivas. Recent Patents for Predictive and Prognostic Biomarkers in Non-Small-Cell
Lung Cancer. Recent Patents on Biomarkers 2011; 1(2):119-138.
11. Grivas P, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H.
Estrogen receptor α/β, AIB1 and TIF2 in colorectal carcinogenesis: do co-regulators have
prognostic significance? Int Journal of Colorectal Disease 2009;24(6):613-22. PMID: 19198856
12. Tzelepi V, Grivas P, Kefalopoulou Z, Kalofonos H, Varakis J, Melachrinou M, Bonikou-Sotiropoulou
G. Estrogen signaling in colorectal carcinoma microenvironment: Expression of ERβ1, AIB-1 and
TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.
Virchows Archiv 2009;454(4):389-99. PMID: 19277704
13. V Tzelepi, P Grivas, Z Kefalopoulou, H Kalofonos, J Varakis, G Sotiropoulou-Bonikou. Expression
of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of
colorectal carcinomas. Cytoplasmic translocation of NCoR in epithelial cells correlates with better
prognosis. Virchows Archiv 2009;454(1):41-53. PMID: 19048289
14. PD Grivas, V Tzelepi, G Sotiropoulou-Bonikou, Z Kefalopoulou, AG Papavassiliou, H Kalofonos.
Expression of ERα, ERβ and co-regulator PELP1/MNAR in colorectal cancer: prognostic
significance and clinicopathologic correlations. Cellular Oncol 2009;31(3):235-47. PMID: 19478391
15. A. Antonacopoulou, F. Dimitrakopoulos, A. Kottorou, S. Marousi, M. Palli, K. Floratou, P. Grivas, C.
Scopa, H. Kalofonos. “Survivin -31G/C polymorphism is related to overall survival in colorectal
cancer”. Annals of Oncology 2008;19 Suppl8:viii140.
16. H Kalofonos, PD Grivas. “Recent advances in the signal transduction targeting of colorectal cancer:
the paradigm of translational medicine”; Current Signal Transduction Therapy 2009;4(1), 6-21(16).
17. V Tzelepi, P Grivas, Z Kefalopoulou, H Kalofonos, M Melachrinou, G Sotiropoulou-Bonikou.
Expression of estrogen receptors α and β and steroid receptor coregulators (AIB-1, TIF-2) at the
invasion front of colorectal carcinomas. Histopathology 2008;53 Suppl1:1-431 (p:382).
18. V Tzelepi, Z Kefalopoulou, P Grivas, H Kalofonos, M Melachrinou, G Sotiropoulou-Bonikou.
Estrogen dependent signaling in cancer microenviroment: ERB, AIB-1 and TIF-2 are upregulated in
myofibroblasts contributing to colorectal carcinogenesis. Histopathology 2008;53 S1:1–431 (p:383).
19. PD Grivas, A Antonakopoulou, V Tzelepi, G Sotiropoulou-Bonikou, Z Kefalopoulou, AG
Papavassiliou, H Kalofonos. “HER-3 in colorectal tumourigenesis: from mRNA levels through
protein status to clinicopathologic relationships”; EJC 2007;43:2602-11. PMID: 17920261
20. AG Antonacopoulou, P Grivas, L Skarlas, M Kalofonos, HP Kalofonos. “POLR2F, ATP6V0A1 and
PRNP expression in colorectal cancer: new molecules with prognostic significance?” Anticancer
Research 3-4/2008;28(2B):1221-7. PMID: 18505059
Selected Extramural Invited Presentations
1. 2013: Grivas P, Day KC, Daignault S, Shakir N, Paul A, Kunju P, Smith DC, Hussain M, Day
ML. Investigation of a novel irreversible pan-HER inhibitor combined with chemotherapy in
bladder cancer models. 2013 Annual ASCO Meeting, abstract #4545
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
2. 2013: Grivas P, Daignault S, Cooney KA, Jacobson J, Yablon C, Ross BD, Chenevert TL,
Galbán CJ, Rehemtulla A, Keller ET, Kunju P, Mehra R, Escara-Wilke J, Shelley G, Pienta KJ,
Hussain M, Smith DC. A phase II trial of cabozantinib (Cabo) in patients (pts) with castrateresistant prostate cancer (CRPC) metastatic to bone (NCT01428219). 2013 Annual ASCO
Meeting, abstract TPS5094
3. 2013: Grivas P, Karatsinides A, Day KC, Kunju P, Paul A, Shakir N, Keller ET, Hussain M, Day ML.
Evaluation of a novel irreversible pan-HER inhibitor in bladder cancer models. 2013 ASCO GU Cancers
Symposium; Abstract # 253
4. 2012: Grivas P, Agarwal N, Siefker-Radtke AO, Daignault S, Puzanov I, MacVicar GR, Levine EG,
Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC,
Day ML, Smith DC, Hussain M. Randomized Phase II Trial of Gemcitabine/Cisplatin with or without
Cetuximab in Patients with Advanced Urothelial Carcinoma (NCT00645593). 2012 Annual ASCO Meeting;
Abstract #4506
5. 2012: Grivas P, Nanus DM, Stadler WM, Daignault S, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ,
Bylow KA, Belldegrun AS, Sottnik JL, Keller ET, Smith DC, Hussain M. Randomized phase II trial of
maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with
advanced urothelial carcinoma (UC). 2012 ASCO GU Cancers Symposium; Abstract #265
6. 2012: Sweis RF, Grivas P, Pearson AT, Day KC, Day ML, Hussain M. Expression of MET and HGF
in bladder cancer tumorigenesis and invasion. 2012 ASCO Annual Meeting, Abstract # 4573 [J Clin Oncol
30, 2012 (suppl; abstr 4573)]
7. 2011: Smith DC, Grivas P, Daignault S, Hafez K, Wood DP, Lee CT, Montie JE, Weizer AZ,
Montgomery J, Hussain M. A Phase II trial of neoadjuvant ABI-007, carboplatin and gemcitabine (ACG) in
patients with locally advanced carcinoma of the bladder. 2011 ASCO GU Cancers Symposium; Abst #244
8. 2011: Signal transduction targeting in cancer: where do we stand? “Advances in Oncology”
Seminar, Patras, Greece
9. 2011: Signal transduction targeting in cancer: from bench to bedside; Seminar room, Dept. of
Biological Chemistry, Medical School, University of Athens, Greece
10. 2009: A rare case of intracranial tumor lysis; ACP Southeastern Chapter Conference, Philadelphia.
11. 2008: A. Antonacopoulou, F. Dimitrakopoulos, A. Kottorou, S. Marousi, M. Palli, K. Floratou, P.
Grivas, C. Scopa, H. Kalofonos. “Survivin -31G/C polymorphism is related to overall survival in colorectal
cancer”; 33rd ESMO Congress, Stockholm, Sweden
12. 2008: A. Kottorou, AG. Antonacopoulou, PD. Grivas, L. Skarlas, CD. Scopa, HP. Kalofonos. “NFYC expression in colorectal cancer”; 7th Congress of the Balcan Union of Oncology, Kuşadasi, Turkey
13. 2008: “Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis: a case
report”, 9th Annual Perspectives in Colorectal Cancer, Miami, Florida
14. 2008: “Post-transplantation lymphoproliferative disorder twenty years after heart transplantation”;
ACP Southeastern Chapter Conference, Philadelphia, PA
15. 2007: “The role of HER\erbB family receptors in CaCO-2 and DLD-1 colorectal cancer cell lines”;
Conference: Modern management of malignancies and future perspectives
16. 2007: “Monoclonal antibodies in the targeted therapy of colorectal cancer”; 8th International
Conference: Medicinal Chemistry – Drug Discovery and Design
Book chapters




Kalofonos HP, Grivas PD. “The role of monoclonal antibodies in the management of solid tumors”;
Chapter 59, Biological Factors, Clinical Oncology - Section A, 2007
Grivas P, Davenport M, Montie JE, Kunju LP, Feng F, Weizer AZ. “Urethral cancer”; Dr. Eslick’s issue
of Hematology/Oncology Clinics of North America devoted to “Rare Cancers” Hematol Oncol Clin North
Am. 2012;26(6):1291-314. PMID: 23116581
Grivas PD, Weizer AZ, Hussain M: Bladder Cancer. "Oncology boards flash review”. Worden F,
Khoriaty R, (eds.) New York, NY: Demos Medical, 2013.
Grivas PD, Smith DC: Testicular Cancer. "Oncology boards flash review”. Worden F, Khoriaty R, (eds.)
New York, NY: Demos Medical, 2013.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page